Relevant bibliographies by topics / Targeted therapy of hematological malignancies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Targeted therapy of hematological malignancies'

Author: Grafiati
Published: 11 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Targeted therapy of hematological malignancies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Targeted therapy of hematological malignancies"

1

Kachlany, Scott C., Amy Le, and Benjamin A. Belinka. "Leukotoxin (Leukothera™), a Targeted Therapy for Hematological Malignancies." Blood 116, no. 21 (2010): 3284. http://dx.doi.org/10.1182/blood.v116.21.3284.3284.

Full text
Abstract:
Abstract Abstract 3284 Leukotoxin (Leukothera™) is a bacterial protein toxin that naturally targets and kills disease associated white blood cells (WBCs) expressing the activated form of leukocyte function antigen-1 (LFA-1). While leukotoxin has minimal effects on resting and healthy cells, it causes significant death of malignant WBCs associated with leukemias and lymphomas. Leukotoxin is a unique biologic in that it already provides both toxicity and specificity without requiring fusion of the protein to other molecules such as antibody fragments or cytokines. In vivo efficacy was demonstrat
APA, Harvard, Vancouver, ISO, and other styles
2

Kuriakose, Philip. "Targeted Therapy for Hematologic Malignancies." Cancer Control 12, no. 2 (2005): 82–90. http://dx.doi.org/10.1177/107327480501200203.

Full text
Abstract:
Background: The introduction of monoclonal antibodies, either as native molecules or conjugated to radioisotopes or other toxins, has led to new therapeutic options for patients with hematologic malignancies. In addition, the use of small molecules against specific cell surface receptors, enzymes, and proteins has become an important strategy in the treatment of such disorders. Methods: The author reviewed the published clinical trials of monoclonal antibody and other targeted therapies in hematologic malignancies. Results: Results from several trials demonstrate a therapeutic benefit for the
APA, Harvard, Vancouver, ISO, and other styles
3

Joshi, Dolly, Kanjaksha Gosh, and Babu Rao Vundinti. "MicroRNAs in hematological malignancies: a novel approach to targeted therapy." Hematology 17, no. 3 (2012): 170–75. http://dx.doi.org/10.1179/102453312x13376952196656.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mandala, Evdokia, Kyranna Lafara, Dimitrios Kokkinovasilis, et al. "Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review." Life 14, no. 4 (2024): 524. http://dx.doi.org/10.3390/life14040524.

Full text
Abstract:
Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related
APA, Harvard, Vancouver, ISO, and other styles
5

Podhorecka, Monika, Justyna Markowicz, Agnieszka Szymczyk, and Johannes Pawlowski. "Target Therapy in Hematological Malignances: New Monoclonal Antibodies." International Scholarly Research Notices 2014 (October 30, 2014): 1–16. http://dx.doi.org/10.1155/2014/701493.

Full text
Abstract:
Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies. MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significant antitumor activity. This review provides an overview of the functional characteristics of MoAbs, with some examples of their clinical application. The promising results in the treatment of hematological malignancies have led to the more frequent usage of MoAbs in the therapy. Development of MoAbs
APA, Harvard, Vancouver, ISO, and other styles
6

Ma, Haiqing, Saradhi Mallampati, Gang An, and Jin Wang. "Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice." BioMed Research International 2015 (2015): 1–2. http://dx.doi.org/10.1155/2015/157570.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Das, Kaushik, Tanmoy Mukherjee, and Prem Shankar. "The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy." Biomolecules 13, no. 6 (2023): 897. http://dx.doi.org/10.3390/biom13060897.

Full text
Abstract:
The tumor microenvironment (TME) plays an important role in the development and progression of hematological malignancies. In recent years, studies have focused on understanding how tumor cells communicate within the TME. In addition to several factors, such as growth factors, cytokines, extracellular matrix (ECM) molecules, etc., a growing body of evidence has indicated that extracellular vesicles (EVs) play a crucial role in the communication of tumor cells within the TME, thereby contributing to the pathogenesis of hematological malignancies. The present review focuses on how EVs derived fr
APA, Harvard, Vancouver, ISO, and other styles
8

Li, Xinglan, Mengyu Xu, Yanying Chen, et al. "Metabolomics for hematologic malignancies: Advances and perspective." Medicine 103, no. 38 (2024): e39782. http://dx.doi.org/10.1097/md.0000000000039782.

Full text
Abstract:
With the use of advanced technology, metabolomics allows for a thorough examination of metabolites and other small molecules found in biological specimens, blood, and tissues. In recent years, metabolomics has been recognized that is closely related to the development of malignancies in the hematological system. Alterations in metabolomic pathways and networks are important in the pathogenesis of hematologic malignancies and can also provide a theoretical basis for early diagnosis, efficacy evaluation, accurate staging, and individualized targeted therapy. In this review, we summarize the prog
APA, Harvard, Vancouver, ISO, and other styles
9

Leni, Zaira, Geetha Parakkal, and Alexandre Arcaro. "Emerging Metabolic Targets in the Therapy of Hematological Malignancies." BioMed Research International 2013 (2013): 1–12. http://dx.doi.org/10.1155/2013/946206.

Full text
Abstract:
During the last decade, the development of anticancer therapies has focused on targeting neoplastic-related metabolism. Cancer cells display a variety of changes in their metabolism, which enable them to satisfy the high bioenergetic and biosynthetic demands for rapid cell division. One of the crucial alterations is referred to as the “Warburg effect”, which involves a metabolic shift from oxidative phosphorylation towards the less efficient glycolysis, independent of the presence of oxygen. Although there are many examples of solid tumors having altered metabolism with high rates of glucose u
APA, Harvard, Vancouver, ISO, and other styles
10

Bogdanovic, Bojana, Florent Hugonnet, and Christopher Montemagno. "Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy." Cancers 17, no. 7 (2025): 1247. https://doi.org/10.3390/cancers17071247.

Full text
Abstract:
Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, continue to challenge clinicians with complex treatment regimens that often involve significant side effects and limited success, especially in advanced stages. Recent advancements in nuclear medicine have introduced theranostic strategies that merge diagnostic imaging with targeted therapeutic approaches, offering the potential for more precise and personalized treatment. A key area of progress lies in the development of alpha-emitting radiopharmaceuticals, such as 225Ac, 211At, or 212Pb, which can deliver potent ra
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Targeted therapy of hematological malignancies"

1

Amdouni, Hela. "Synthèse et étude de nouveaux analogues de l’acadésine pour circonvenir les résistances dans les hémopathies malignes." Thesis, Université Côte d'Azur (ComUE), 2016. http://www.theses.fr/2016AZUR4065/document.

Full text
Abstract:
La lutte contre le cancer est certainement l’un des défis majeurs de ce 21ème siècle. Les résistances qui émergent contre les agents de thérapie ciblée présentent un aspect particulièrement épineux de cette problématique. La thèse présentée ici s’inscrit dans ce cadre. Elle vise à développer des molécules bioactives pouvant circonvenir les résistances apparues contre les traitements de certaines hémopathies malignes : la leucémie myéloïde chronique (LMC) et le syndrome myélodysplasique (SMD). Après avoir mis au point une méthodologie de synthèse monotope permettant de transformer un azoture en
APA, Harvard, Vancouver, ISO, and other styles
2

Jokinen, E. (Elina). "Targeted therapy sensitivity and resistance in solid malignancies." Doctoral thesis, Oulun yliopisto, 2014. http://urn.fi/urn:isbn:9789526205755.

Full text
Abstract:
Abstract Cancer is a major global killer and a challenge for the healthcare worldwide. Earlier cancer has been treated with surgery, radiation, chemotherapy and hormonal therapy. Unfortunately the efficiency of these therapies has shown to be limited and this has raised an enthusiasm for development of new, targeted cancer therapies that are based on activated oncogenes. The challenge of the targeted therapies is therapy resistance, de novo, adaptive and acquired. This work investigated targeted therapy sensitivity and resistance in lung cancer, breast cancer, colorectal cancer, and melanoma c
APA, Harvard, Vancouver, ISO, and other styles
3

Lundin, Jeanette. "Targeted CD52 therapy in lymphoid malignancies : a clinical and immunological study /." Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-441-0/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Günther, Thomas [Verfasser], Hans-Jürgen [Akademischer Betreuer] Wester, Matthias [Gutachter] Eiber, and Hans-Jürgen [Gutachter] Wester. "Novel GRPR-targeted antagonists with improved pharmacokinetics for imaging and therapy of GRPR-expressing malignancies / Thomas Günther ; Gutachter: Matthias Eiber, Hans-Jürgen Wester ; Betreuer: Hans-Jürgen Wester." München : Universitätsbibliothek der TU München, 2021. http://d-nb.info/1233428055/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

DELLA, CRISTINA Pietro Argeo. "Construction of a macromolecular recombinant drug for the targeted therapy of hematological malignancies." Doctoral thesis, 2009. http://hdl.handle.net/11562/337455.

Full text
Abstract:
L’impiego di agenti citotossici capaci di riconoscere in modo specifico molecole presenti sulla superficie di una cellula tumorale rappresenta una tecnica molto promettente per il trattamento di diverse neoplasie ed è particolarmente efficace per la cura di leucemie e linfomi. Appartengono a questa classe di sostanze le immunotossine, proteine composte da un dominio di derivazione anticorpale e da un dominio tossico solitamente di origine batterica o vegetale: l’anticorpo lega selettivamente l’antigene bersaglio e, a seguito di endocitosi, consente il rilascio all’interno della cellula d
APA, Harvard, Vancouver, ISO, and other styles
6

CASTAGNA, Monica. "Targeting CD38 antigen as a therapeutic strategy for hematological malignancies." Doctoral thesis, 2013. http://hdl.handle.net/11562/537549.

Full text
Abstract:
Il successo di terapie convenzionali come la chemioterapia e la radioterapia per il trattamento delle neoplasie è stato limitato a causa di diversi fattori come la chemioresistenza ai farmaci e la tossicità periferica causata dalla mancanza di specificità di questi approcci. Per questo motivo l’interesse per le terapie selettive che prevedono l’uso di immunotossine, specialmente per il trattamento di tumori ematologici, è in aumento. Le immunotossine sono proteine chimeriche costituite da un ligando selettivo per la cellula bersaglio (dominio di origine anticorpale, citochina o fattore di cres
APA, Harvard, Vancouver, ISO, and other styles
7

Huang, Chia Ju, and 黃佳如. "Cognitive behavioral therapy for depression and anxiety in patients with hematological malignancies." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/65385533412867466652.

Full text
Abstract:
碩士<br>長庚大學<br>護理學系<br>99<br>Purpose: Examine the effect of cognitive behavioral therapy on depression and anxiety in hospitalized patients with hematological malignancies. Method: A prospective study with randomization was used. Patients were assigned to one of the three groups: (1) cognitive behavioral therapy (CBT) group (n =17) ( 2) attention control group (n =19), and (3) usual-care control group (n =20). Patients in the cognitive behavioral therapy group received 6 individual CBT interventions for a total of 6 hours. Patients in the attention control group received listening support for a
APA, Harvard, Vancouver, ISO, and other styles
8

Abdelfatah, Possnert Heba. "Detection of Thymidine Kinase 1 Activity in Whole Blood Using an Oligonucleotide System." Thesis, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-349265.

Full text
Abstract:
In today’s medical science studies, many tumor markers are being used to monitor cancer cell proliferation, but the number of assays for analysis of these markers are few. The aim of this study was to find an easier and more time-efficient way to measure the activity of a specific tumor marker called tymidine kinase 1 (TK1). This tumor marker is an important enzyme involved in cell proliferation and is a key enzyme in the salvage pathway. TK1 activity is related to the occurrence of hematological malignancies and cell activity and therefore have been used as a marker when monitoring this group
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Targeted therapy of hematological malignancies"

1

Quintás-Cardama, Alfonso. Targeted therapy for solid tumors and hematologic malignancies. Nova Science Publishers, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1946-, Cheson Bruce D., ed. Monoclonal antibody therapy of hematologic malignancies. Darwin Scientific, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kleinberg, Michael. Managing infections in patients with hematological malignancies. Humana Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ansell, Stephen M., and Various. Rare Hematological Malignancies. Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ansell, Stephen M. Rare Hematological Malignancies. Springer, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cimpean, Anca Maria, Andreea Adriana Jitariu, and Marius Raica. Growth Factors and Their Corresponding Receptors as Targets for Ovarian Cancer Therapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0011.

Full text
Abstract:
Ovarian cancer remains one of the most aggressive and difficult to manage malignancies regarding evaluation and therapeutic options. The high mortality persists despite extensive research in the field. Current conventional chemotherapy does not improve disease-free survival and does not decrease recurrences amongst patients. This calls for a stringent reconsideration of the drugs selection, focused on the most targeted strategies and personalization of the therapy. Targeted agents against growth factors and their corresponding receptors are already approved as first- or second-line neoadjuvant
APA, Harvard, Vancouver, ISO, and other styles
7

Pereira, Luis F., Mark Bradley, Harold W. Goforth, et al. Overview of HIV-Associated Multimorbidities. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0047.

Full text
Abstract:
With the advent of effective antiretroviral therapy, persons with access to and engagement in HIV medical care and antiretroviral therapy can live longer and remain healthy with what has become a chronic manageable illness. Despite advances in medical care, without access to HIV medical care and antiretroviral therapy or with access but without viral suppression, persons with HIV still experience opportunistic infections and cancers. This chapter reviews the HIV-associated multimorbidities, including pulmonary manifestations, ophthalmological complications, dermatological manifestations, gastr
APA, Harvard, Vancouver, ISO, and other styles
8

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Biomarkers and cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0040.

Full text
Abstract:
Biomarkers and cancer defines these markers and outlines their role in diagnosis, prognosis, prediction of response, and response assessment of a variety of cancers. Established biomarkers are reviewed, and the potential for development of new biomarkers offered by the dramatic progress in both the understanding of molecular biology and the development of laboratory techniques is emphasised. The field of signal transduction has already proved fruitful, with identification of markers allowing successful targeted therapy in a range of cancers. Progress is anticipated also in tumour imaging, with
APA, Harvard, Vancouver, ISO, and other styles
9

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Principles of chemotherapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0005.

Full text
Abstract:
Principles of radiation oncology outlines the physical and biological effects of ionising radiation, and its use in clinical oncology. Radiobiology, examining the response of tissue to ionising radiation, is described with regards to normal and malignant tissues. The effect of fractionation, the delivery of radiotherapy in a series of repeated exposures, is examined. The damaging effects on normal tissues are considered, particularly nonreversible late effects including carcinogenesis. Therapeutic exposure to ionising radiation is contrasted between radical and palliative radiotherapy. The phy
APA, Harvard, Vancouver, ISO, and other styles
10

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Malignancy of unknown primary. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0026.

Full text
Abstract:
Bone and soft tissue malignancies describes a large group of sarcomas, some of which require highly specialist management, including osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma, so that referral to an appropriate multidisciplinary team (MDT) is mandatory. Limb conserving surgery combined with pre- and postoperative chemotherapy is curative in the majority of osteosarcomas, and similar approach which may include local radiotherapy also holds for Ewing’s. Other primary bone tumours are reviewed including malignant fibrous histiocytoma, chondrosarcoma, chordoma, solitary plasmacytoma, and
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Targeted therapy of hematological malignancies"

1

Zehnbauer, Barbara, and Mona Nasser. "Targeted Therapy in Hematologic Malignancies." In Hematopathology. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-262-9_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Booth, Christopher H., Lysette Mutkus, Karen Bussard, Erika Spaeth, Michael Andreeff, and Frank C. Marini. "Mesenchymal Stem/Stromal Cell-Targeted Therapies for Solid Tumors and Hematological Malignancies." In Targeted Therapy of Acute Myeloid Leukemia. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1393-0_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ayag, Hatice, Sehmus Ertop, Muzeyyen Aslaner Ak, and Birsen Sahip Yesiralioglu. "Immunotherapy in Hematological Malignancy." In Immunotherapy in Human Cancers. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359388.4.

Full text
Abstract:
Tumor immune tolerance represents a significant obstacle to effective cancer therapy. A multitude of pathways through which tumors evade immune surveillance have been identified . These developments have prompted a reevaluation of the "hallmarks of cancer" and have spurred the development of numerous promising immunotherapies. Various categories of immunotherapies, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies, have been devised for treating hematologic cancers, with ongoing
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, Yizhuo, Shanqi Guo, and Haifeng Zhao. "Epigenetic Regulation and Therapy in Lymphoid Malignancies." In Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-5028-9_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mounier, Nicolas, and Michelle A. Rudek. "Chemotherapy and Interactions with Combination Antiretroviral Therapy." In HIV-associated Hematological Malignancies. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26857-6_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Barta, Stefan K. "Coinfection with Hepatitis B or C in People Living with HIV Undergoing Immunosuppressive Therapy." In HIV-associated Hematological Malignancies. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26857-6_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ramesh, Sathyadeepak. "Targeted Therapy for Cutaneous Malignancies." In Foundational Papers in Oculoplastics. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92794-3_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Furukawa, Nobufusa, and Ali Guermazi. "Abdominal Effects of Therapy in Patients Treated for Hematological Malignancies." In Radiological Imaging in Hematological Malignancies. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18832-9_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hanna, Soheil L., and Barry D. Fletcher. "Musculoskeletal Effects of Therapy in Patients Treated for Hematological Malignancies." In Radiological Imaging in Hematological Malignancies. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18832-9_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Herbrecht, Raoul, and Yasmine Nivoix. "Antifungal Therapy in Patients with Hematological Malignancies." In Pulmonary Involvement in Patients with Hematological Malignancies. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-15742-4_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Targeted therapy of hematological malignancies"

1

Shah, Neil P. "Abstract IA16: Acquired resistance to targeted therapeutics in hematologic malignancies." In Abstracts: AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; June 18-21, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.pms14-ia16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Abid, Muhammad Bilal, Aniko Szabo, Timothy S. Fenske, et al. "231 Infectious complications in patients with hematologic malignancies receiving CD19 vs. BCMA targeted CAR-T therapy." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pearson, Jennifer M., Su-Fern Tan, Arati Sharma, et al. "Abstract 48: Acid ceramidase inhibition: A targeted therapy for acute myeloid leukemia." In Abstracts: Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; May 6-9, 2017; Boston, MA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1557-3265.hemmal17-48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Eckfeldt, Craig E., Robin DW Lee, Emily J. Pomeroy, et al. "Abstract B01: Mechanisms of treatment resistance following Ras targeted therapy in acute myeloid leukemia." In Abstracts: AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; September 20-23, 2014; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.hemmal14-b01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Medichelme, Chaitanya, Shagun Juneja, Anirudh Punnakal, et al. "Retrospective analysis of acute and late gastrointestinal and hematological toxicities with extended field radiation in gynaecological malignancies: A single institution data." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685352.

Full text
Abstract:
Purpose: The aim of this study is to report a preliminary analysis of our clinical experience with extended field pelvic (conformal) radiation, with or without concurrent chemotherapy, in gynaecological malignancies. Materials and Methods: 27 women with gynaecological malignancies (17 with Carcinoma Cervix and 10 with Carcinoma Endometrium) were treated between November 2009 and October 2015 with Extended Field abdomino-pelvic radiation. All patients were treated with conformal radiation (Intensity Modulated Radiotherpy or Volumetric Modulated Arc Therapy). All patients underwent CT Simulation
APA, Harvard, Vancouver, ISO, and other styles
6

Shah, Chintan, Yan Gong, Anita Szady, et al. "Abstract 987: Unanticipated cardiotoxicity due to targeted anti-cancer therapy in hematologic malignancies patients: Natural history and risk factors." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-987.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gusi-Vives, M., O. Collazo, A. Meler, et al. "Targeted modulation of HDAC7 improves the outcome of hematological malignancies." In 35. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1786583.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Choudhury, Yukti, Chae Yin Cher, Min-Han Tan, and Zi Yi Lim. "Abstract A41: Ultrasensitive detection of diverse genomic alterations in hematological malignancies using a targeted amplicon-based sequencing approach." In Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-a41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lau, Christopher C., Keith Killian, Yuelin J. Zhu, et al. "Abstract 1999: A targeted exome sequencing platform for routine clinical molecular profiling of advanced thoracic malignancies relevant to targeted therapy." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1999.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Poortinga, Gretchen, Jeannine Diesch, Elaine Sanij, et al. "Abstract A31: Elucidating mechanisms that cooperate with the therapeutic inhibition of RNA polymerase I to treat MYC-driven hematological malignancies." In Abstracts: AACR Special Conference on Myc: From Biology to Therapy; January 7-10, 2015; La Jolla, CA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3125.myc15-a31.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Targeted therapy of hematological malignancies"

1

Zhao, Kangjia, Jiwen Sun, Nanping Shen, et al. Treatment-Related Adverse Events of Chimeric Antigen receptor T-Cell (CAR-T) Cell Therapy in B-cell hematological malignancies in the Pediatric and Young Adult Population: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Marenco-Hillembrand, Lina, Michael A. Bamimore, Julio Rosado-Philippi, et al. The Evolving Landscape of Leptomeningeal Cancer from Solid Tumors: A Systematic Review of Clinical Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.12.0112.

Full text
Abstract:
Review question / Objective: Among adult patients with leptomeningeal carcinomatosis from solid tumors (population) treated with chemotherapy, targeted therapy, or immunotherapy (intervention and comparator) what are the differences in overall survival (OS) and progression-free survival (PFS) and treatment response based on clinical trial outcomes? Eligibility criteria: Included articles reported 1) human subjects ≥ 18 years 2) diagnosis of leptomeningeal carcinomatosis from solid tumors confirmed by imaging or cerebrospinal fluid (CSF) cytology and clinical or neurological symptoms 3) clinica
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Targeted therapy of hematological malignancies' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography